Bibliographical noteFunding Information:
Drs Nambi, Ballantyne, and Hoogeveen are coinventors on a provisional patent (patent #61721475) titled “Biomarkers to Improve Prediction of Heart Failure Risk,” filed by Roche Diagnostics and Baylor College of Medicine on their behalf. Dr Matsushita reports nonfinancial support from Roche Diagnostics outside the submitted work. Dr Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, BMS, Celladon, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, Novartis, Sanofi Pasteur, and Theracos and has consulted for Akros, Alnylam, Amgen, AoBiome, AstraZeneca, Bayer, BMS, Cardiac Dimensions, Cardurion, Corvia, Gilead, GSK, Ironwood, Janssen, Merck, Novartis, Roche, Quantum Genetics, Takeda, and Theracos. None of these supported the current research. Dr Shah has received research support from Novartis through the Brigham and Women’s Hospital and consulting fees from GlaxoSmithKline and Philips Ultrasound. Dr de Lemos has received grant support from Abbott Diagnostics and Roche Diagnostics and consulting income from Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel, Inc, Radiometer, and Roche Diagnostics. Dr de Lemons is also coinventor on a patent issued to the University of Maryland using high-sensitivity cardiac troponin T and left ventricular hypertrophy as markers of heart failure risk (patent no. 61990386). Dr Ballantyne is a consultant for Roche Diagnostics and Abbott Diagnostics. Dr. Jia, W. Sun, and Drs Folsom, Heiss, Couper, Boerwinkle, and Selvin have stated that they have no actual or potential perceived conflicts of interests.